{"brief_title": "An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder", "brief_summary": "A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder (MDD)", "condition": ["Major Depressive Disorder (MDD)"], "intervention_type": ["Drug"], "intervention_name": ["Radafaxine"], "criteria": "Inclusion Criteria: - Diagnosis of Major Depressive Disorder (MDD) - Duration of current depressive episode 12 weeks - 24 months - Patients can read and write at a level sufficient to provide a signed consent - If female, patients must be practicing an acceptable method of birth control Exclusion Criteria: - Patients have other psychiatric disorders that would affect patient's response to treatment - Patients have not responded to two or more adequate courses of antidepressant therapy - Patients cannot be currently abusing illicit drugs or alcohol - Patients are not currently receiving psychotherapy - Patients have received electroconvulsive therapy within 6 months prior to screening - Patients are pregnant or lactating", "gender": "All", "minimum_age": "18 Years", "maximum_age": "64 Years", "healthy_volunteers": "No", "keyword": "MDD", "mesh_term": ["Disease", "Depressive Disorder", "Depression", "Depressive Disorder, Major"], "id": "NCT00057239"}